Vai trò của Immmunoglobulin trong Bệnh Thán huyết tân sinh do Rhesus

Filbey D, Hanson U, Wesstrom G. The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995; 74: 687–92 Clarke C, Hussey RMSO. Decline in deaths from rhesus haemolytic disease of the newborn. J R Coll Physicians Lond 1994; 28(4): 310–1 Whitfield CR, Raffat A, Urbaniak S. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review. Br Med J 1997; 315(7121): 1504–5 Newman TB, Klebanoff MA. Neonatal hyperbilirubinemia and long term outcome: another look at the collaborative perinatal project. Pediatrics 1993; 92: 651–7 Stewart G, Day RE, Del Priore C, et al. Developmental outcome after intravascular intrauterine transfusion for rhesus haemolytic disease. Arch Dis Child 1994; 70(1): F52–3 Johnston WH, Angara V, Baumal R, et al. Erythroblastosis fetalis and hyperbilirubinaemia: a five-year follow up with neurological psychological and audiological evaluation. Pediatrics 1967; 39(1): 88–92 Nilsen ST, Finne PH, Bergsjo P, et al. Males with neonatal hyperbilirubinaemia examined at 18 years of age. Acta Paediatr Scand 1984; 73(2): 176–180 Craig S, Morris K, Tubman T, et al. The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland. Ir Med J 2000; 93(1): 17–8 Greenough A, Yüksel B, Nicolaides KH. Abnormalities of lung volume at follow up following antenatal rhesus iso-immunization. Acta Paediatr 1994; 83: 498–500 Chamberlain D, Hislop A, Hey E, et al. Pulmonary hypoplasia in babies with severe rhesus isoimmunisation: a quantitative study. J Pathol 1977; 122(1): 43–52 Mollison PL, Engelfreit CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oford: Blackwell Scientific Publications, 1993 Standing Medical Advisory Committee (SMAC). Memorandum on Haemolytic Disease of the Newborn Addendum 1981. Lndon: Department of Health and Social Security, 1982 Joint Working Group of the British Transfusion Society and the Royal College of Obstetricians and Gynaecologists. Recommendations for the use anti-D immunoglobulin for Rh prophylaxis. Transfus Med 1999; 9: 93–7 Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation (Cochrane review). In: The Cochrane Library. Issue 3. Oford: Update Software,2000 Tovey LAD. Towards the conquest of Rh haemolytic disease: Britain’s contribution and the role of serendipity. Transfus Med 1992; 2: 99–109 Howard HL, Martlew VJ, McFayen IR, et al. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynaecol 1997; 104: 37–41 NTBS Immunoglobulin Working Party. Recommendations for use of anti D immunoglobulin. Prescribers Journal 1991; 31: 137–45 Bowman JM, Chown JM, Lewis M, et al. Rh-immunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978; 118:623–7 Tovey LAD, Townley A, Stevenson BJ, et al. The Yorkshire antenatal anti D immunoglobulin trial in primigravida. Lancet 1983; 2: 244–6 Huchet J, Dallemagne S, Huchet C, et al. Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region [French]. J Gynecol Obstet Biol Reprod (Paris) 1987; 16(1): 101–11 Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med 1995; 5(1): 15–9 Proceedings of the Joint Royal College of Physicians of Edinburgh and the Royal College of Obstetricians and Gynaecologists Consensus Conference on Anti D Prophylaxis; 1997 Apr 8–9; Edinburgh. Br J Obstet Gynaecol 1997; 105 (17 Suppl.) Hartwell EA. Use of Rhimmune globulin. Am J Clin Path 1998; 110:281–92 Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. Br J Obstet Gynaecol 1998; 105: 129–34 Adams MM, Marks JS, Koplan JP. Cost implications of routine antenatal administration of Rh immune globulin. Am J Obstet Gynecol 1984; 149: 633–8 Baskett FT, Parson ML. Prevention of rhesus (D) allo immunization: a cost benefit analysis. Can Med Assoc J 1990; 142: 337–9 Selinger M. Immunoprophlaxis for rhesus disease — expensive but worth it? Br J Obstet Gynaecol 1991; 98: 509–12 de Crespigny L, Davison G. Anti-D administration in early pregnancy - time for a new protocol. Aust NZ J Obstet Gynecol 1995; 35(4): 385–7 Watanabe KK, Busch MP, Schrieber GB, et al. Evaluation of safety of Rh immunoglobulin by monitoring viral markers among Rh-negative female blood donors. Vox Sang 2000; 78: 1–6 Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type I. Transfusion 1999; 39: 1160–8 Fletcher A, Thomson A. The introduction of human monoclonal anti D for therapeutic use. Transfus Med Rev 1995; 9: 314–26 Armstrong-Fisher SS, Carter MC, Downing I, et al. Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgGl and IgG3 antibodies on their in vitro biologic function. Transfusion 1999; 39(9): 1005–2 Hadley AG. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Vox Sang 1998; 74 Suppl. 2: 375–83 Dooren MC, Kuijpers RW, Joekes EC, et al. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR). Lancet 1992; 339: 1067–70 Shepard SL, Noble AL, Filbey D, et al. Inhibition of the monocyte chemiluminescent response to anti-D-sensitized red cells by Fc gamma RI-blocking antibodies which ameliorate the severity of haemolytic disease of the newborn. Vox Sang 1996; 70(3): 157–63 Neppert J, v Witzleben-Schurholz E, Zupanska B, et al. High incidence of maternal HLA A, B and C antibodies associated with a mild course of haemolytic disease of the newborn. Group for the Study of Protective Maternal HLA Antibodies in the Clinical Course of HDN. Eur J Haematol 1999; 63(2): 120–5 Newman TB, Maiseis MJ. Evaluation of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992; 89: 809–18 Dodd KL. Neonatal jaundice — a lighter touch. Arch Dis Child 1993; 68: 529–33 Nicolaides KH, Rodeck CH. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. Br Med J 1992; 304: 1155–6 Nicolini U, Kochenour NK, Greco P, et al. Consequences of fetomaternal haemorrhage after intrauterine transfusion. Br Med J 1988; 297: 1379–81 Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342(1): 9–14 Nicolaides KH, Clewell WH, Ibashan RS, et al. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet 1988; 1: 1073–5 Gottvall T, Selbing A. Alloimmunization during pregnancy treated with high dose intravenous immunoglobulin. Acta Obstet Gynecol Scand 1995; 74: 777–83 Harman CR. Invasive techniques in the management of allo-immune anaemia. In: Harman CR, editor. Invasive fetal testing and treatment. Boston: Blackwell Scientific, 1995: 107–12 Harman CR, Bowman JM, Manning FA, et al. Intrauterine transfusion — intraperitoneal versus intravascular approach: a case-control comparison. Am J Obstet Gynecol 1990; 162(4): 1053–9 Luban NLC, De Palma L. Transfusion associated graft versus host disease in the neonate — expanding the spectrum of disease. Transfusion 1996; 36: 101–3 Naiman JL, Punnett HH, Lischner HW, et al. Possible graft versus host reaction after intrauterine transfusion for Rh erythroblastosis fetalis. N Engl J Med 1969; 281(13): 697–701 Parkman R, Mosier D, Umansky J, et al. Graft versus host disease after intrauterine and exchange transfusions for haemolytic disease of the newborn. N Engl J Med 1974; 290: 359–63 Scaradavou A, Inglis S, Peterson P, et al. Suppression of erythropoiesis by intrauterine transfusions in hemolytic disease of the newborn: use of erythropoietin to treat the late anemia. J Pediatr 1993; 123: 279–84 Allen FH, Diamond LK, Vaughan VC. Erythroblastosis fetalis VI. Prevention of kernicterus. Am J Dis Child 1950; 80: 779–91 Mollison PL, Walker W. Controlled trials of the treatment of haemolytic disease of the newborn. Lancet 1952; 262: 429 Cochran WD. Increasing safety of exchange transfusion. Pediatr Res 1978; 12:462 Valaes T, Kipouros K, Petmezaki S, et al. Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice. Pediatr Res 1980; 14: 947–52 Blackburn MG, Orzalesi MM, Pigram P. The combined effect of phototherapy and phenobarbital on serum bilirubin levels of premature infants. Pediatrics 1972; 49(1): 110–2 Valdes OS, Maurer HM, Shumway CN, et al. Controlled clinical trial of phenobarbital and/or light in reducing neonatal hyperbilirubinaemia in a predominantly Negro population. J Pediatr 1971; 79(6): 1015–7 Kappas A, Drummond GS, Manola T, et al. Sn protoporphyrin use in the management of hyperbilirubinaemia in term new-borns with direct Coombs-positive ABO incompatibility. Pediatrics 1988; 81: 485–97 Hayde M, Widness JA, Pollak C, et al. Rhesus isoimmunization: increased hemolysis during early infancy. Pediatr Res 1997; 41(5): 716–21 Kirsten GF, Steyn DW, Muller L, et al. The outcome of babies of mothers with severe rhesus incompatibility treated at Tygerberg Hospital, 1980–1993. S Afr Med J 1995; 85(Suppl. 10): 1091–6 Ennever JF. Blue light, green light, white light, more light: treatment of neonatal jaundice. Clin Perinatol 1990; 17: 467–81 Millard DD, Gidding SS, Socol ML, et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal haemolysis and erythropoiesis in severe fetal isoimmunisation. J Pediatr 1990; 117: 447–54 Ovali F, Samanci N, Dagoglu T. Management of late anemia in rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res 1996; 39(5): 831–4 Berlin G, Selbing A, Ryden GSO. Rhesus haemolytic disease treated with high-dose intravenous immunoglobulin. Lancet 1985; 1(8438): 1153 Sacker RA, King JC. Intravenous gamma-globulin in pregnancy: a review. Obstet Gynecol 1988; 44: 25–34 de la Camara C, Arrieta R, Gonzalez A, et al. High-dose intravenous immunoglobulin as the sole prenatal treatment for severe Rh immunization. N Engl J Med 1988; 318(8): 519–20 Rewald E. Intravenous gammaglobulin to prevent stillbirth in rhesus incompatibility. Lancet 1985; 2(8448): 208 Chitkara U, Bussel J, Alvarez M, et al. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis? Obstet Gynecol 1990; 76(4): 703–8 Rewald E, Suringar F. Tolerance of intravenous gamma globulin. Bibl Haematol 1968; 29: 337–9 Urbaniak SJ, Duncan Jl, Armstrong-Fisher SS, et al. Variable inhibition of placental IgG transfer in vitro with commercial rVgG preparations. Br J Haematol 1999; 107: 815–7 Palfi M, Hilden JO, Gottvall T, et al. Placental transport of maternal immunoglobulin G in pregnancies at risk of Rh (D) hemolytic disease of the newborn. Am J Reprod Immunol 1998; 39(5): 323–8 Ulm B, Kirchner L, Svolba G, et al. Immunoglobulin administration to fetuses with anemia due to alloimmunization to D. Transfusion 1999; 39(11-12): 1235–8 Fraser ID, Bothamley JE, Bennett MO, et al. Intensive antenatal plasmapheresis in severe rhesus isoimmunization. Lancet 1976; 1: 6–8 Bowman JM. Hemolytic disease of the newborn. Vox Sang 1996; 70: 62–7 Riibo J, Wahn V High-dose immunoglobulin therapy of hyperbilirubinemia in rhesus incompatibility [German]. Infusionsther Transfusionsmed 1993; 20(Suppl. 1): 104–8; discussion: 109 Derycke M, Dreyfus M, Ropert JC, et al. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia. Arch Dis Child 1985; 60(7): 667–9 Voto LS, Sexer H, Ferreiro G, et al. Neonatal administration of high dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med 1995; 23: 443–51 Dagoglu T, Ovali F, Samanci N, et al. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995; 23: 264–71 Rübo J, Albrecht K, Lasch P, et al. High dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992; 121: 93–7 Urbaniak SJSO. ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. II. Investigation into the mechanism of lysis. Br J Haematol 1979; 42(2): 315–25 Massey GV, McWilliams NB, Mueller DG, et al. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987; 111(1): 133–5 Sato K, Hara T, Kondo T, et al. High-dose intravenous gamma-globulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 1991; 80: 163–6 Alpay F, Sarici SU, Okutan V, et al. High dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999; 88: 216–9 CopeIan EA, Strohm PL, Kennedy MS, et al. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26(5): 410–2